Showing results (1-10 of 1,573) with videos related to
Sort By:
Pageof 158
Functional & Integrative Genomics|July 8, 2026
Integrative bulk and single-cell analyses implicate ASL in MIF-associated myeloid programs in glioblastomaWenjing Zhao, Shenglan Li, Wenbin LiFuture Science OA|August 13, 2025
Liposomal honokiol enhance the anti-tumor effect of bevacizumab in glioblastoma by inhibiting autophagyPei Xun, Jiabao Zong, Shenglan Li, et al.American Journal of Translational Research|September 11, 2020
MiRNA-27a-3p induces temozolomide resistance in glioma by inhibiting NF1 levelShenglan Li, Wei Li, Gang Chen, et al.Frontiers in Oncology|April 17, 2025
Preliminary investigation of gut microbiota and associated metabolic pathways in the pathogenesis of primary central nervous system lymphomaZhuang Kang, Rong Zhang, Shenglan Li, et al.Cancer Innovation|September 29, 2025
Re-Innovation in Clinical Trial Designs Based on Precision TherapyShenglan Li, Jiachen Wang, Zhuang Kang, et al.Cancer Innovation|December 13, 2023
Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastomaYuekun Wang, Shenglan Li, Yichen Peng, et al.Translational Cancer Research|March 12, 2026
Exploring the lactate-metabolism related characteristics during the development of medulloblastoma through single-cell and bulk RNA-seqCe Wang, Rong Zhang, Shenglan Li, et al.Iranian Journal of Biotechnology|November 19, 2025
Single-Cell RNA-Seq Dissects Specific Marker in Glioblastoma Based on Gene Regulatory NetworksShenglan Li, Yanjie Lan, Jiachen Wang, et al.Neoplasia (New York, N.Y.)|February 19, 2025
Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomasMengqian Huang, Zhuang Kang, Shenglan Li, et al.Cancer Immunology, Immunotherapy : CII|May 30, 2026
A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastomaXin Yang, Shenglan Li, Yanjie Lan, et al.Pageof 158